The Biologics News and Reports Portal

Show Cart

All Products

Results 121 - 140 of 189

Sep 2014 Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins

200.00 €

Aug 2014 Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

350.00 €

Jul 2014 Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

1,462.50 €

1,950.00 €

(Discount: 25.00%)

Jul 2014 Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors

200.00 €

Jun 2014 Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors

200.00 €

Mar 2014 Competitor Analysis: Cancer Vaccines

800.00 €

Mar 2014 2013 Sales of Recombinant Therapeutic Antibodies & Proteins

25.00 €

Jan 2014 Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis

2,150.00 €

Jan 2014 Competitor Analysis: Immunocytokines

250.00 €

Nov 2013 Competitor Analysis: Janus Kinase (JAK) and spleen tyrosine kinase (syk) Inhibitors

400.00 €

Oct 2013 Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)

500.00 €

Oct 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

1,450.00 €

Sep 2013 Competitor Analysis: Pim Kinase Inhibitors

150.00 €

Sep 2013 Competitor Analysis: Wnt Pathway Inhibitors

100.00 €

Aug 2013 Competitor Analysis: Bruton’s Tyrosine Kinase (BTK) Inhibitors

100.00 €

Aug 2013 Competitor Analysis: Focal Adhesion Kinase (FAK) Inhibitors

100.00 €

Shopping cart

Cart empty

Latest report

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Featured Products

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Latest Target Pipeline

STING Agonists & Antagonists

Shopping cart

Cart empty

Latest report

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Featured Products

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

All Products

Oct 2014 Competitor Analysis: Ebola Virus Vaccines and Therapeutics

Oct 2014 Competitor Analysis: Anti-Infective Peptides

Oct 2014 Competitor Analysis: Cardiovascular Peptides

Sep 2014 Competitor Analysis: Anti-Inflammatory Peptides

Sep 2014 Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins

Aug 2014 Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Jul 2014 Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

Jul 2014 Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors

Jun 2014 Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors

Mar 2014 Competitor Analysis: Cancer Vaccines

Mar 2014 2013 Sales of Recombinant Therapeutic Antibodies & Proteins

Jan 2014 Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis

Jan 2014 Competitor Analysis: Immunocytokines

Nov 2013 Competitor Analysis: Janus Kinase (JAK) and spleen tyrosine kinase (syk) Inhibitors

Oct 2013 Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)

Oct 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

Sep 2013 Competitor Analysis: Pim Kinase Inhibitors

Sep 2013 Competitor Analysis: Wnt Pathway Inhibitors

Aug 2013 Competitor Analysis: Bruton’s Tyrosine Kinase (BTK) Inhibitors

Aug 2013 Competitor Analysis: Focal Adhesion Kinase (FAK) Inhibitors

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing